These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34695137)

  • 21. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma.
    Karray-Chouayekh S; Baccouche S; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    Acta Histochem; 2011 Sep; 113(5):508-13. PubMed ID: 20598349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
    Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
    BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of p53 Overexpression with Hormone Receptor Status and Triple Negative Breast Carcinoma.
    Qamar S; Khokhar MA; Farooq S; Ashraf S; Humayon WA; Rehman A
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):164-167. PubMed ID: 30700357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam.
    Dang Cong T; Nguyen Thanh T; Nguyen Phan QA; Hoang Thi AP; Nguyen Tran BS; Nguyen Vu QH
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1135-1142. PubMed ID: 32334482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MMP-1 expression has an independent prognostic value in breast cancer.
    Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
    BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
    Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
    Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.
    Morrison DH; Rahardja D; King E; Peng Y; Sarode VR
    Br J Cancer; 2012 Jul; 107(2):382-7. PubMed ID: 22713661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
    Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
    Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p63 expression is associated with high histological grade, aberrant p53 expression and TP53 mutation in HER2-positive breast carcinoma.
    Guo S; Wang Y; Rohr J; Shang L; Ma J
    J Clin Pathol; 2021 Oct; 74(10):641-645. PubMed ID: 32873702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
    Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
    Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
    Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
    Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
    Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
    Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.